U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharma's formulation manufacturing facility based out of Baddi, India between June 13, 2022 and June 22, 2022.
Harish Kuber, Company Secretary & Compliance Officer, Glenmark Pharma said, The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
- Read more about U.S. FDA issued Form 483 with six observations at Glenmark Pharma
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/usfda-issued-form-483-with-six-observations-at-glenmark-pharma
No comments:
Post a Comment